MiR-30a-5p connects EWS-FLI1 and CD99, two major therapeutic targets in Ewing tumor

Oncogene

Volumn 32, Issue 33, 2013, Pages 3915-3921

  Franzetti, G A ^a,b   Laud Duval, K ^a,b   Bellanger, D ^a,b   Stern, M H ^a,b   Sastre Garau, X ^b   Delattre, O ^a,b  

^a INSTITUT CURIE   (France)

^b INSTITUT CURIE   (France)

Author keywords

CD99; Ewing sarcoma; EWS FLI1; microRNAs; miR 30a 5p

Indexed keywords

CD99 ANTIGEN; FLI1 PROTEIN; MEMBRANE PROTEIN; MICRORNA; MIR 30A 5P; RNA BINDING PROTEIN EWS; TUMOR MARKER; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG TARGETING; EWING SARCOMA; FEMALE; GENETIC TRANSCRIPTION; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; MODULATION; MOUSE; NONHUMAN; POSTTRANSCRIPTIONAL GENE SILENCING; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTIGENS, CD; BLOTTING, WESTERN; BONE NEOPLASMS; CELL ADHESION MOLECULES; CELL LINE, TUMOR; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, SCID; MICRORNAS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ONCOGENE PROTEINS, FUSION; PROTO-ONCOGENE PROTEIN C-FLI-1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA-BINDING PROTEIN EWS; SARCOMA, EWING; TRANSPLANTATION, HETEROLOGOUS;

EID: 84882454447     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.403     Document Type: Article

References (54)

1. Delattre O, Zucman J, Plougastel B, Desmaze C, Melot T, Peter M et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 1992; 359: 162-165.
2. Erkizan HV, Uversky VN, Toretsky JA. Oncogenic partnerships: EWS-FLI1 protein interactions initiate key pathways of Ewings sarcoma. Clin Cancer Res 2010; 16: 4077-4083.
3. Toomey EC, Schiffman JD, Lessnick SL. Recent advances in the molecular pathogenesis of Ewings sarcoma. Oncogene 2010; 29: 4504-4516.
4. Chansky HA, Hu M, Hickstein DD, Yang L. Oncogenic TLS/ERG and EWS/Fli-1 fusion proteins inhibit RNA splicing mediated by YB-1 protein. Cancer Res 2001; 61: 3586-3590.
5. Sanchez G, Delattre O, Auboeuf D, Dutertre M. Coupled alteration of transcription and splicing by a single oncogene: boosting the effect on cyclin D1 activity. Cell Cycle 2008; 7: 2299-2305.
6. Yang L, Chansky HA, Hickstein DD. EWS.Fli-1 fusion protein interacts with hyperphosphorylated RNA polymerase II and interferes with serine-arginine protein-mediated RNA splicing. J Biol Chem 2000; 275: 37612-37618.
7. Braunreiter CL, Hancock JD, Coffin CM, Boucher KM, Lessnick SL. Expression of EWS-ETS fusions in NIH3T3 cells reveals significant differences to Ewings sarcoma. Cell Cycle 2006; 5: 2753-2759.
8. May WA, Gishizky ML, Lessnick SL, Lunsford LB, Lewis BC, Delattre O et al. Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation. Proc Natl Acad Sci USA 1993; 90: 5752-5756.
9. Castillero-Trejo Y, Eliazer S, Xiang L, Richardson JA, Ilaria Jr RL. Expression of the EWS/FLI-1 oncogene in murine primary bone-derived cells Results in EWS/FLI-1- dependent, Ewing sarcoma-like tumors. Cancer Res 2005; 65: 8698-8705.
10. Riggi N, Cironi L, Provero P, Suva ML, Kaloulis K, Garcia-Echeverria C et al. Development of Ewings sarcoma from primary bone marrow-derived mesenchymal progenitor cells. Cancer Res 2005; 65: 11459-11468.
11. Bernard G, Raimondi V, Alberti I, Pourtein M, Widjenes J, Ticchioni M et al. CD99 (E2) up-regulates alpha4beta1-dependent T cell adhesion to inflamed vascular endothelium under flow conditions. Eur J Immunol 2000; 30: 3061-3065.
12. Schenkel AR, Mamdouh Z, Chen X, Liebman RM, Muller WA. CD99 plays a major role in the migration of monocytes through endothelial junctions. Nat Immunol 2002; 3: 143-150.
13. Bernard G, Breittmayer JP, de Matteis M, Trampont P, Hofman P, Senik A et al. Apoptosis of immature thymocytes mediated by E2/CD99. J Immunol 1997; 158: 2543-2550.
14. Pettersen RD, Bernard G, Olafsen MK, Pourtein M, Lie SO. CD99 signals caspaseindependent T cell death. J Immunol 2001; 166: 4931-4942.
15. Sohn HW, Shin YK, Lee IS, Bae YM, Suh YH, Kim MK et al. CD99 regulates the transport of MHC class I molecules from the Golgi complex to the cell surface. J Immunol 2001; 166: 787-794.
16. Bremond A, Meynet O, Mahiddine K, Coito S, Tichet M, Scotlandi K et al. Regulation of HLA class I surface expression requires CD99 and p230/golgin-245 interaction. Blood 2009; 113: 347-357.
17. Cerisano V, Aalto Y, Perdichizzi S, Bernard G, Manara MC, Benini S et al. Molecular mechanisms of CD99-induced caspase-independent cell death and cell-cell adhesion in Ewings sarcoma cells: actin and zyxin as key intracellular mediators. Oncogene 2004; 23: 5664-5674.
18. Scotlandi K, Baldini N, Cerisano V, Manara MC, Benini S, Serra M et al. CD99 engagement: an effective therapeutic strategy for Ewing tumors. Cancer Res 2000; 60: 5134-5142.
19. Sohn HW, Choi EY, Kim SH, Lee IS, Chung DH, Sung UA et al. Engagement of CD99 induces apoptosis through a calcineurin-independent pathway in Ewings sarcoma cells. Am J Pathol 1998; 153: 1937-1945.
20. Kreppel M, Aryee DN, Schaefer KL, Amann G, Kofler R, Poremba C et al. Suppression of KCMF1 by constitutive high CD99 expression is involved in the migratory ability of Ewings sarcoma cells. Oncogene 2006; 25: 2795-2800.
21. Rocchi A, Manara MC, Sciandra M, Zambelli D, Nardi F, Nicoletti G et al. CD99 inhibits neural differentiation of human Ewing sarcoma cells and thereby contributes to oncogenesis. J Clin Invest 2010; 120: 668-680.
22. Miyagawa Y, Okita H, Nakaijima H, Horiuchi Y, Sato B, Taguchi T et al. Inducible expression of chimeric EWS/ETS proteins confers Ewings family tumor-like phenotypes to human mesenchymal progenitor cells. Mol Cell Biol 2008; 28: 2125-2137.
23. Riggi N, Suva ML, Suva D, Cironi L, Provero P, Tercier S et al. EWS-FLI-1 expression triggers a Ewings sarcoma initiation program in primary human mesenchymal stem cells. Cancer Res 2008; 68: 2176-2185.
24. Hu-Lieskovan S, Zhang J, Wu L, Shimada H, Schofield DE, Triche TJ. EWS-FLI-1 fusion protein up-regulates critical genes in neural crest development and is responsible for the observed phenotype of Ewings family of tumors. Cancer Res 2005; 65: 4633-4644.
25. Rorie CJ, Thomas VD, Chen P, Pierce HH, OBryan JP, Weissman BE. The Ews/Fli-1 fusion gene switches the differentiation program of neuroblastomas to Ewing sarcoma/peripheral primitive neuroectodermal tumors. Cancer Res 2004; 64: 1266-1277.
26. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006; 6: 259-269.
27. Ban J, Jug G, Mestdagh P, Schwentner R, Kauer M, Aryee DN et al. Hsa-mir-145 is the top EWS-FLI1-repressed microRNA involved in a positive feedback loop in Ewings sarcoma. Oncogene 2011; 30: 2173-2180.
28. McKinsey EL, Parrish JK, Irwin AE, Niemeyer BF, Kern HB, Birks DK et al. A novel oncogenic mechanism in Ewing sarcoma involving IGF pathway targeting by EWS/Fli1-regulated microRNAs. Oncogene 2011; 30: 4910-4920.
29. Riggi N, Suva ML, De Vito C, Provero P, Stehle JC, Baumer K et al. EWS-FLI-1 modulates miRNA145 and SOX2 expression to initiate mesenchymal stem cell reprogramming toward Ewing sarcoma cancer stem cells. Genes Dev 2010; 24: 916-932.
30. De Vito C, Riggi N, Suva ML, Janiszewska M, Horlbeck J, Baumer K et al. Let-7a is a direct EWS-FLI-1 target implicated in Ewings sarcoma development. PLoS ONE 2011; 6: e23592.
31. Lessnick SL, Dacwag CS, Golub TR. The Ewings sarcoma oncoprotein EWS/FLI induces a p53-dependent growth arrest in primary human fibroblasts. Cancer Cell 2002; 1: 393-401.
32. Tirode F, Laud-Duval K, Prieur A, Delorme B, Charbord P, Delattre O. Mesenchymal stem cell features of Ewing tumors. Cancer Cell 2007; 11: 421-429.
33. Fabian MR, Sonenberg N, Filipowicz W. Regulation of mRNA translation and stability by microRNAs. Annu Rev Biochem 2010; 79: 351-379.
34. Cironi L, Riggi N, Provero P, Wolf N, Suva ML, Suva D et al. IGF1 is a common target gene of Ewings sarcoma fusion proteins in mesenchymal progenitor cells. PLoS ONE 2008; 3: e2634.
35. Li J, Donath S, Li Y, Qin D, Prabhakar BS, Li P. miR-30 regulates mitochondrial fission through targeting p53 and the dynamin-related protein-1 pathway. PLoS Genet 2010; 6: e1000795.
36. Martinez I, Cazalla D, Almstead LL, Steitz JA, DiMaio D. miR-29 and miR-30 regulate B-Myb expression during cellular senescence. Proc Natl Acad Sci USA. 2011; 108: 522-527.
37. Zaragosi LE, Wdziekonski B, Le Brigand K, Villageois P, Mari B, Waldmann R et al. Small RNA sequencing reveals miR-642a-3p as a novel adipocyte-specific microRNA and miR-30 as a key regulator of human adipogenesis. Genome Biol 2011; 12: R64.
38. Zhong X, Li N, Liang S, Huang Q, Coukos G, Zhang L. Identification of microRNAs regulating reprogramming factor LIN28 in embryonic stem cells and cancer cells. J Biol Chem 2010; 285: 41961-41971.
39. Calin GA, Liu CG, Sevignani C, Ferracin M, Felli N, Dumitru CD et al. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci USA 2004; 101: 11755-11760.
40. Garzon R, Croce CM. MicroRNAs in normal and malignant hematopoiesis. Curr Opin Hematol 2008; 15: 352-358.
41. Bandres E, Cubedo E, Agirre X, Malumbres R, Zarate R, Ramirez N et al. Identification by real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues. Mol Cancer 2006; 5: 29
42. Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 2008; 299: 425-436.
43. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006; 9: 189-198.
44. Budhu A, Jia HL, Forgues M, Liu CG, Goldstein D, Lam A et al. Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology 2008; 47: 897-907.
45. Szafranska AE, Davison TS, John J, Cannon T, Sipos B, Maghnouj A et al. MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene 2007; 26: 4442-4452.
46. Baffa R, Fassan M, Volinia S, OHara B, Liu CG, Palazzo JP et al. MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets. J Pathol 2009; 219: 214-221.
47. Yu F, Deng H, Yao H, Liu Q, Su F, Song E. Mir-30 reduction maintains self-renewal and inhibits apoptosis in breast tumor-initiating cells. Oncogene 2010; 29: 4194-4204.
48. Kumarswamy R, Mudduluru G, Ceppi P, Muppala S, Kozlowski M, Niklinski J et al. MicroRNA-30a inhibits epithelial-to-mesenchymal transition by targeting snai1 and is downregulated in non-small cell lung cancer. Int J Cancer 2011; 130: 2044-2053.
49. Melot T, Dauphinot L, Sevenet N, Radvanyi F, Delattre O. Characterization of a new brain-specific isoform of the EWS oncoprotein. Eur J Biochem 2001; 268: 3483-3489.
50. Melot T, Gruel N, Doubeikovski A, Sevenet N, Teillaud JL, Delattre O. Production and characterization of mouse monoclonal antibodies to wild-type and oncogenic FLI-1 proteins. Hybridoma 1997; 16: 457-464.
51. Lee MT, Coburn GA, McClure MO, Cullen BR. Inhibition of human immunodeficiency virus type 1 replication in primary macrophages by using Tat- or CCR5- specific small interfering RNAs expressed from a lentivirus vector. J Virol 2003; 77: 11964-11972.
52. Fujita S, Iba H. Putative promoter regions of miRNA genes involved in evolutionarily conserved regulatory systems among vertebrates. Bioinformatics 2008; 24: 303-308.
53. Boeva V, Surdez D, Guillon N, Tirode F, Fejes AP, Delattre O et al. De novo motif identification improves the accuracy of predicting transcription factor binding sites in ChIP-Seq data analysis. Nucleic Acids Res 2010; 38: e126.
54. Guillon N, Tirode F, Boeva V, Zynovyev A, Barillot E, Delattre O. The oncogenic EWS-FLI1 protein binds in vivo GGAA microsatellite sequences with potential transcriptional activation function. PLoS ONE 2009; 4: e4932.